uniQure N.V. 
QURE is a leading gene therapy biotech targeting rare diseases like Huntington’s and hemophilia.
🔹 Bullish setup forming above $14.50–$15.00
🔹 Price Target: $28.00–$29.00
📈 Catalyst: FDA alignment on its Huntington’s program (AMT-130) clears the path for a BLA submission in Q1 2026, significantly derisking the development.
✅ Early data from AMT-130 is promising, tracking well with clinical and biomarker endpoints — potential first-mover in disease-modifying therapies for Huntington’s.
🧠 Expanding platform: AMT-260 (epilepsy) delivered a 92% seizure reduction in initial patient, showcasing pipeline breadth across CNS disorders.
🧬 QURE offers exposure to the fast-growing gene therapy space with high long-term upside potential if clinical momentum continues.
#QURE #GeneTherapy #BiotechStocks #FDA #BreakoutSetup #LongSetup #RareDiseases #HuntingtonsDisease #Epilepsy #SmallCapStocks #GrowthStocks #Healthcare #BiotechInvesting #TechnicalAnalysis #StockWatchlist #Bullish
QURE is a leading gene therapy biotech targeting rare diseases like Huntington’s and hemophilia.🔹 Bullish setup forming above $14.50–$15.00
🔹 Price Target: $28.00–$29.00
📈 Catalyst: FDA alignment on its Huntington’s program (AMT-130) clears the path for a BLA submission in Q1 2026, significantly derisking the development.
✅ Early data from AMT-130 is promising, tracking well with clinical and biomarker endpoints — potential first-mover in disease-modifying therapies for Huntington’s.
🧠 Expanding platform: AMT-260 (epilepsy) delivered a 92% seizure reduction in initial patient, showcasing pipeline breadth across CNS disorders.
🧬 QURE offers exposure to the fast-growing gene therapy space with high long-term upside potential if clinical momentum continues.
#QURE #GeneTherapy #BiotechStocks #FDA #BreakoutSetup #LongSetup #RareDiseases #HuntingtonsDisease #Epilepsy #SmallCapStocks #GrowthStocks #Healthcare #BiotechInvesting #TechnicalAnalysis #StockWatchlist #Bullish
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.